Kelun-Biotech

Kelun-Biotech. A leading biopharmaceutical company in China focused on the research, development, and commercialization of innovative biological therapies. Established as a subsidiary of the major pharmaceutical firm Sichuan Kelun Pharmaceutical Co., Ltd., it has rapidly advanced a pipeline centered on oncology and autoimmune disease treatments. The company leverages advanced platforms in antibody-drug conjugate and monoclonal antibody technologies to address significant unmet medical needs globally.

Company Overview

Founded in 2016, Kelun-Biotech operates as a core biotech entity within the broader Kelun Group conglomerate, which has a long history in the pharmaceutical industry of China. Its headquarters and primary research facilities are strategically located in Chengdu High-tech Zone, a hub for technological innovation. Under the leadership of Chairman Liu Gexin, the company has pursued an aggressive growth strategy, expanding its workforce to over a thousand employees specializing in drug discovery, clinical development, and commercialization. The firm's mission is aligned with national initiatives like Made in China 2025, aiming to elevate the country's standing in the global biopharmaceutical sector.

Research and Development

The company's research and development engine is powered by several proprietary technology platforms, most notably its OptiDC platform for designing novel antibody-drug conjugate therapies. Its scientists, many recruited from leading global institutions like the National Institutes of Health and F. Hoffmann-La Roche, conduct extensive work at its Good Laboratory Practice-certified labs in Sichuan. Key R&D focuses include bispecific antibodies, immuno-oncology agents targeting checkpoints like PD-1, and next-generation ADCs with improved therapeutic indices. The pipeline is managed through a milestone-driven process, with numerous candidates undergoing trials at prestigious hospitals such as Peking University Cancer Hospital.

Product Portfolio

Kelun-Biotech's portfolio features a mix of late-stage clinical assets and commercialized products. Its most advanced candidate, an antibody-drug conjugate targeting HER2-positive cancers, has shown promising results in global Phase III clinical trials. Another significant asset is a PD-L1 inhibitor being developed for various solid tumor indications, which has received Breakthrough Therapy Designation from the National Medical Products Administration. The company has also successfully launched several biosimilar products, including versions of bevacizumab and rituximab, which are marketed through partnerships with Sinopharm Group and other major drug distributors across Asia.

Collaborations and Partnerships

Strategic alliances are a cornerstone of the company's business model. A landmark collaboration with the American firm Mersana Therapeutics focuses on co-developing novel ADCs using Mersana's Dolaflexin platform. Additionally, Kelun-Biotech has entered into a significant licensing agreement with Harbour BioMed to access its HCAb technology for generating fully human antibodies. The company maintains research partnerships with academic powerhouses like Sichuan University and the Chinese Academy of Sciences, and its commercial partnerships extend to firms like Fresenius Kabi for market expansion in Europe and Latin America.

Financial Performance

As a privately held subsidiary, detailed financials are not fully public, but its performance is reflected in the disclosures of its parent company, Sichuan Kelun Pharmaceutical Co., Ltd., listed on the Shenzhen Stock Exchange. Significant capital has been raised through private equity rounds from investors like Hillhouse Capital Group and Boyu Capital, funding its expansive clinical programs. Revenue streams are growing from early product sales and substantial upfront payments from partnerships, such as the deal with Mersana Therapeutics. The company's valuation has risen sharply, positioning it as a potential candidate for an Initial public offering on the Hong Kong Stock Exchange or NASDAQ in the future.

Category:Biotechnology companies of China Category:Pharmaceutical companies established in 2016 Category:Companies based in Chengdu